May 7, 2015

Life sciences

 

Medicago awarded a contract by the U.S. Department of Health and Human Services to explore alternate production methods for Ebola antibodies

Medicago awarded a contract by the U.S. Department of Health and Human Services to explore alternate production methods for Ebola antibodies

Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority (BARDA) at the U.S. Department of Health and Human Services (HHS) for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp™, from Mapp Biopharmaceutical.

 

Opsens announces first use of its FFR products in Europe with Dr De Bruyne

Opsens Inc. ("Opsens") (TSXV:OPS) is pleased to announce the first use of its Fractional Flow Reserve ("FFR") products in Europe by the "founding fathers" of FFR, namely Dr. Bernard De Bruyne at the Cardiovascular Center Aalst, Belgium and, shortly, by Professor Nico Pijls, at  the Catharina Hospital, Eindhoven the Netherlands. The OptoWire and OptoMonitor are Opsens' products for FFR measurements to optimize the diagnosis and guide the therapy in patients with coronary heart disease.

 

GenePOC finalized its funding with Debiopharm Diagnostics and Emerillon Capital

Debiopharm Diagnostics, part of Debiopharm Group™, is proud to be the lead investor in GenePOC, who are developing a highly innovative, low cost and quick MDx (Molecular Diagnostics) platform. Debiopharm Diagnostics led this investment round together with Emerillon Capital and will become the largest shareholder in GenePOC.

 

New expertise in human-derived biological products - Héma-Québec researchers save a young boy's sight

A young boy in Stoneham owes his sight to the work of a team of researchers from Héma-Québec and a product they developed using a derivative of plasma, the liquid portion of blood that contains a variety of proteins.

 

GenePOC on the cusp of a revolution in the field of medical diagnosis Infectious disease diagnosis made fast and easywith GenePOC technology

It will soon be possible to diagnose and identify Clostridium difficile,StaphylococcusStreptococcus, respiratory tract infections, sexually transmitted infections, and a variety of other infectious diseases much faster with cutting edge technology developed by GenePOC, a rapidly expanding Quebec City company.

 

The Québec City Convention Centre will host an international congress on chronic societal cardiometabolic diseases

From July 8 to 12, 2015, between 700 and 800 specialists of abdominal obesity, type 2 diabetes, cardiovascular diseases, nutrition and physical activity will take part in this international scientific event. Close to forty speakers are already confirmed.

 

TSO3 enters into first commercial agreement for STERIZONE® VP4 Sterilizer

TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced that the Company has signed its first commercial agreement with Getinge Infection Control in support of the launch of the STERIZONE® VP4 Sterilization System. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.

 

3rd round of financing of Feldan for $1.2M

Members of Anges Québec, the Anges Québec Capital Fund and Fier Succès reiterated their confidence in Feldan, a Quebec company that develops cell therapy products, with a new investment of over $1.2M. With this third round of financing completed, the biotechnology company can now rely on a $675K investment from 15 angels, including Jean-Marc Rousseau and Sylvain Chartier, $475K from the Anges Québec Capital Fund and $75K from Fier Succès.